Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

981
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
981
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

304
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same author

Circulating biomarkers of bronchoalveolar injury help predict the need for mechanical ventilation in patients with moderate to severe COVID-19 pneumonia: A prospective cohort study.

PloS one·2026
Same author

Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Platelet dense granule defect: experience in the French population.

Research and practice in thrombosis and haemostasis·2026
Same author

Selection and optimization strategy for Rap1-targeting single-domain antibodies as platelet activation markers.

Research and practice in thrombosis and haemostasis·2026
Same author

Effects of Spectral Interfering Substances on Light Transmission Platelet Aggregation Using Infrared Based Aggregometer.

Journal of clinical laboratory analysis·2025

Related Experiment Video

Updated: Dec 28, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K

RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology.

Matthias Canault1, Marie-Christine Alessi1,2

  • 1Aix Marseille University, INSERM, INRAE, C2VN, 13005 Marseille, France.

International Journal of Molecular Sciences
|February 12, 2020
PubMed
Summary
This summary is machine-generated.

RasGRP2 protein variants cause platelet-type bleeding disorder-18 (BDPLT18), a new inherited bleeding condition. This review covers RasGRP2

Keywords:
RasGRP2inherited platelet disorderplatelet

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

949
Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

1.1K

Related Experiment Videos

Last Updated: Dec 28, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

949
Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

1.1K

Area of Science:

  • Biochemistry
  • Hematology
  • Genetics

Background:

  • RasGRP2 is a guanine nucleotide exchange factor crucial for platelet activation.
  • It regulates Rap1 signaling, essential for alpha-IIb-beta-3 integrin function.
  • Variants in RASGRP2 lead to platelet dysfunction and bleeding disorders.

Purpose of the Study:

  • To review the structure and function of RasGRP2.
  • To discuss its role in platelet pathophysiology and other cell types.
  • To examine pathogenic variants and management strategies for BDPLT18.

Main Methods:

  • Literature review of RasGRP2 structure and function.
  • Analysis of reported pathogenic variants in RASGRP2.
  • Summary of diagnostic and management approaches for BDPLT18.

Main Results:

  • RasGRP2's role in Rap1 activation and integrin signaling is detailed.
  • Platelet-type bleeding disorder-18 (BDPLT18) is characterized by RASGRP2 variants.
  • Various pathogenic variants and their clinical implications are presented.

Conclusions:

  • RasGRP2 is vital for normal platelet function.
  • Mutations in RASGRP2 cause BDPLT18, a distinct congenital bleeding disorder.
  • Understanding RasGRP2 variants aids in diagnosing and managing patients.